UBS’s Regulus Therapeutics RGLS Stock Holding History

UBS’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$11K	Buy	+13	New	+$11K	﹤0.01%	8732

Other funds holding RGLS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

AWMDMG

Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return

UBS's RGLS Position: Q3 2014 in Review

UBS reduced its Regulus Therapeutics (RGLS) stake by 17% in Q3 2014, selling an estimated $11.8K and leaving 67 shares worth $55K. The position accounts for ﹤0.01% of the portfolio, ranked #6711.

UBS first reported a position in RGLS in Q2 2013 and has held it in 6 quarters since. The position peaked at $83K in Q3 2013. 49 funds tracked by Wall St. Rank hold RGLS as of Q3 2014.

UBS held 67 shares of Regulus Therapeutics worth $55K as of Q3 2014.
UBS sold 14 Regulus Therapeutics shares in Q3 2014, an estimated $11.8K.
Regulus Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #6711 holding.
UBS first reported a position in Regulus Therapeutics in Q2 2013 and has held it in 6 quarters since.
UBS's Regulus Therapeutics position peaked at $83K in Q3 2013.
49 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.